Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Applying to University of Kansas Cancer Center - North · Kansas City, Missouri
Answer a few short questions to share with the research team.